Guggenheim Reaffirms Buy Rating for Pfizer (NYSE:PFE)

Pfizer (NYSE:PFE)‘s stock had its “buy” rating reissued by equities research analysts at Guggenheim in a report released on Wednesday,Benzinga reports.

A number of other equities research analysts also recently commented on the stock. Truist Financial cut their target price on shares of Pfizer from $36.00 to $32.00 and set a “buy” rating for the company in a research report on Wednesday, December 18th. UBS Group reduced their price objective on Pfizer from $31.00 to $29.00 and set a “neutral” rating for the company in a research report on Wednesday, January 8th. Bank of America reissued a “neutral” rating and issued a $29.00 target price on shares of Pfizer in a research report on Tuesday, December 10th. StockNews.com lowered shares of Pfizer from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, November 20th. Finally, Wolfe Research initiated coverage on shares of Pfizer in a report on Friday, November 15th. They issued an “underperform” rating and a $25.00 price objective on the stock. One research analyst has rated the stock with a sell rating, eight have issued a hold rating, six have given a buy rating and three have given a strong buy rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $31.92.

Pfizer Stock Down 0.4 %

Pfizer stock opened at $25.60 on Wednesday. Pfizer has a 12 month low of $24.48 and a 12 month high of $31.54. The stock has a fifty day simple moving average of $26.26 and a two-hundred day simple moving average of $27.17. The company has a current ratio of 1.00, a quick ratio of 0.73 and a debt-to-equity ratio of 0.63. The firm has a market cap of $145.08 billion, a price-to-earnings ratio of 18.16, a PEG ratio of 0.64 and a beta of 0.61.

Pfizer (NYSE:PFE) last released its quarterly earnings data on Tuesday, February 4th. The biopharmaceutical company reported $0.63 EPS for the quarter, topping the consensus estimate of $0.48 by $0.15. The company had revenue of $17.76 billion during the quarter, compared to the consensus estimate of $17.26 billion. Pfizer had a return on equity of 19.47% and a net margin of 12.62%. Pfizer’s revenue for the quarter was up 24.7% on a year-over-year basis. During the same period last year, the company earned $0.10 EPS. Equities analysts predict that Pfizer will post 2.95 EPS for the current fiscal year.

Insider Buying and Selling at Pfizer

In related news, Director Ronald E. Blaylock acquired 19,457 shares of the business’s stock in a transaction on Thursday, February 13th. The stock was acquired at an average cost of $25.65 per share, with a total value of $499,072.05. Following the acquisition, the director now directly owns 27,707 shares in the company, valued at $710,684.55. This represents a 235.84 % increase in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. Insiders own 0.06% of the company’s stock.

Hedge Funds Weigh In On Pfizer

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Swedbank AB boosted its stake in Pfizer by 0.7% during the third quarter. Swedbank AB now owns 5,745,831 shares of the biopharmaceutical company’s stock valued at $166,284,000 after buying an additional 37,636 shares during the last quarter. United Bank raised its holdings in shares of Pfizer by 3.7% during the 3rd quarter. United Bank now owns 35,599 shares of the biopharmaceutical company’s stock worth $1,030,000 after acquiring an additional 1,277 shares in the last quarter. WCM Investment Management LLC boosted its position in shares of Pfizer by 337.2% during the 3rd quarter. WCM Investment Management LLC now owns 50,675 shares of the biopharmaceutical company’s stock valued at $1,474,000 after acquiring an additional 39,085 shares during the last quarter. Entropy Technologies LP purchased a new position in shares of Pfizer in the third quarter valued at $860,000. Finally, GSA Capital Partners LLP increased its position in Pfizer by 87.6% in the third quarter. GSA Capital Partners LLP now owns 32,786 shares of the biopharmaceutical company’s stock worth $949,000 after purchasing an additional 15,310 shares during the last quarter. Institutional investors own 68.36% of the company’s stock.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.